34898-30-1

Basic information

• Product Name: 2-[4-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOLE
• Synonyms: 2-[4-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOLE;2-[4-(TrifluoroMethyl)phenyl]iMidazole
• CAS NO: 34898-30-1
• Molecular Formula: C₁₀H₇F₃N₂
• Molecular Weight: 212.18
• Mol File: 34898-30-1.mol
• Article Data: 11

Chemical Properties

• Melting Point: 219-221 °C
• Boiling Point: 327.084 °C at 760 mmHg
• Flash Point: 151.616 °C
• Appearance: /
• Density: 1.328 g/cm³
• PKA: 12.11±0.10(Predicted)
• CAS DataBase Reference: 2-[4-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[4-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOLE(34898-30-1)
• EPA Substance Registry System: 2-[4-(TRIFLUOROMETHYL)PHENYL]-1H-IMIDAZOLE(34898-30-1)

Safety Data

• Hazardous Substances Data: 34898-30-1(Hazardous Substances Data)

Usage

General Description

2-[4-(Trifluoromethyl)phenyl]-1H-imidazole is a chemical compound that belongs to the imidazole family, which is characterized by a five-membered ring containing two nitrogen atoms. The compound has a trifluoromethyl group attached to a phenyl ring, which gives it unique chemical properties. It is commonly used in pharmaceutical research and drug development due to its potential as a bioactive molecule. Its structure and properties make it suitable for use as a building block in the synthesis of various biologically active compounds. Additionally, it has been studied for its potential antimicrobial, antifungal, and anticancer properties, making it a promising candidate for further exploration in the field of medicinal chemistry.

Upstream product

• 455-19-6 4-Trifluoromethylbenzaldehyde 
• 455-18-5 4-CF₃C₆H₄CN 
• 288-32-4 1H-imidazole 
• 455-13-0 4-Iodobenzotrifluoride 
• 208718-17-6 2-(4-(trifluoromethyl)phenyl)-4,5-dihydro-1H-imidazole 

Downstream Products

• 1253697-59-4 1-(phenylsulfonyl)-2-(4-(trifluoromethyl)phenyl)-1H-imidazole 

Relevant articles and documents

Addressing hERG activity while maintaining favorable potency, selectivity and pharmacokinetic properties of PPARδ modulators

One of the most commonly used strategies to reduce hERG (human ether-a-go-go) activity in the drug candidates is introduction of a carboxylic acid group. During the optimization of PPARδ modulators, some of the compounds containing a carboxylic acid were found to inhibit the hERG channel in a patch clamp assay. By modifying the basicity of the imidazole core, potent and selective PPARδ modulators that do not inhibit hERG channel were identified. Some of the modulators have excellent pharmacokinetic profiles in mice.

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.